Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Themis
Biotech
Valneva exceeds protection goal in chikungunya vaccine trial
A phase 3 trial of Valneva’s chikungunya vaccine candidate has hit its primary endpoint, cementing the biotech’s lead over Merck.
Nick Paul Taylor
Aug 5, 2021 7:40am
Merck takes $170M charge on abandoned COVID-19 drug
May 6, 2021 9:00am
Merck inks Themis buyout to join COVID-19 vaccine race
May 26, 2020 7:00am
Themis raises €40M to run phase 3 chikungunya vaccine trial
Sep 18, 2019 5:00am
Merck teams up with Themis to develop vaccines
Aug 22, 2019 5:00am
Themis pulls out of IPO, looks into 'strategic options'
Nov 9, 2018 8:42am
